Creative Biolabs Bispecific Antibody Blog

Menu

Skip to content
  • Bispecific Antibody Research
  • Bispecific Antibody Clinic
  • News

Monthly Archives: March 2019

02Mar/19
Fig. 1 "Don't eat me" signal versus "eat me" signal. (Jiang, 2021)

TG Therapeutics’s new anti-CD47 and CD19 therapy TG-1801 enters Phase I clinical practice

March 2, 2019Bispecific Antibody Clinic, Bispecific Antibody Research, NewsbsAb, CD19-CD47biobsab

TG Therapeutics is a biopharmaceutical company dedicated to developing innovative treatments for patients with B-cell-mediated diseases. Recently, the company announced the launch of TG-1801 ‘s first human Phase I study, a new,Read More…

Categories

  • Bispecific Antibody Clinic
  • Bispecific Antibody Research
  • BSAB
  • Cancer Immunotherapy
  • Events
  • News

Recent Posts

  • ISB 1442: A Novel Bispecific Antibody for Targeting CD38+ Hematologic Malignancies
  • Advancing HIV-1 Therapy: Bispecific Antibodies to Enhance Latent Reservoir Clearance
  • Unveiling a New Mechanism: How CD47 Shields Cancer Cells from Immune Clearance
  • New Cancer Therapy Target May Disrupt Shared Resources Among Tumor Cells
  • Natural Products Targeting Tumor Angiogenesis

Archives

  • March 2024
  • January 2024
  • December 2023
  • November 2023
  • October 2023
  • September 2023
  • August 2023
  • July 2023
  • June 2023
  • May 2023
  • April 2023
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • February 2022
  • March 2021
  • December 2020
  • October 2020
  • August 2020
  • June 2019
  • April 2019
  • March 2019
  • February 2019
  • December 2018
  • November 2018
  • October 2018

Contact Us

USA - UK
Copyright © Creative Biolabs Bispecific Antibody Blog
Powered by WordPress , Theme i-max by TemplatesNext.
MENU
  • Bispecific Antibody Research
  • Bispecific Antibody Clinic
  • News